SLC5A2 and type 2 diabetes mellitus: EMPA-REG OUTCOME trial demonstrated in patients with T2D, sodium-glucose cotransporter 2 inhibitor (SGLT2i), Empagliflozin on top of standard care reduced the risk of 3-point major adverse cardiovascular events (MACE) consisting of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death, compared with placebo [3].